SCHEMBL3023227

SCHEMBL3023227

CC1=CN2CCN1CC2C(=O)OCCN(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
PHLPP2 Q6ZVD8 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CYP2C19 P33261 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
BCHE P06276 2/20 0.33
NPSR1 Q6W5P4 1/20 0.32
POLB P06746 1/20 0.32
PIK3CD O00329 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014343 0.83 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2GAAMAPT
SCHEMBL3022493 0.76 CHRM2 (0.37) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3014714 0.76 CHRM2 (0.37) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3007661 0.75 CHRM2 (0.34) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3009196 0.75 RET (0.35)
SCHEMBL3019833 0.69 CHRM2 (0.41) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3011272 0.67 CHRM2 (0.39) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL13601746 0.66 CHRNB2 (0.41) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL13601767 0.66 CHRNB2 (0.41) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL3020560 0.66 CHRM2 (0.38) CHRM2CHRM1CHRM3CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2010-08-12 US disclosed
EP-2197882-A2 METHOD FOR PRODUCING TEDA DERIVATIVES Basf Se (DE) 2010-06-23 EP disclosed
WO-2009030649-A2 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES TES, TRRAP, NAAA CHRM2 3790/4885CHRM1 4053/4885CHRM3 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.